PP2A-activating drugs selectively eradicate TKI-resistant chronic myeloid leukemic stem cells

The Rac GTPase effector p21-activated kinase is essential for hematopoietic stem/progenitor cell migration and engraftment

(2013) A. M. Dorrance et al.   BLOOD

Protein phosphatase 2A: a target for anticancer therapy

(2013) Danilo Perrotti et al.   LANCET ONCOLOGY

Genetic and Pharmacologic Inhibition of β-Catenin Targets Imatinib-Resistant Leukemia Stem Cells in CML

(2012) Florian H. Heidel et al.   Cell Stem Cell

Chronic myeloid leukemia stem cells are not dependent on Bcr-Abl kinase activity for their survival

(2011) A. Hamilton et al.   BLOOD

(R)-FTY720 methyl ether is a specific sphingosine kinase 2 inhibitor: Effect on sphingosine kinase 2 expression in HEK 293 cells and actin rearrangement and survival of MCF-7 breast cancer cells

(2011) Keng Gat Lim et al.   CELLULAR SIGNALLING

Antitumor effects of OSU-2S, a nonimmunosuppressive analogue of FTY720, in hepatocellular carcinoma

(2011) Hany A. Omar et al.   HEPATOLOGY

In Search of CML Stem Cells’ Deadly Weakness

(2011) Francesca Pellicano et al.   Current Hematologic Malignancy Reports

In search of the original leukemic clone in chronic myeloid leukemia patients in complete molecular remission after stem cell transplantation or imatinib

(2010) M. Sobrinho-Simoes et al.   BLOOD

Bortezomib induces apoptosis in primitive chronic myeloid leukemia cells including LTC-IC and NOD/SCID repopulating cells

(2010) N. B. Heaney et al.   BLOOD

Rac2 GTPase deficiency depletes BCR-ABL+ leukemic stem cells and progenitors in vivo

(2010) A. Sengupta et al.   BLOOD

BCR-ABL enhances differentiation of long-term repopulating hematopoietic stem cells

(2010) M. Schemionek et al.   BLOOD

Effective Targeting of Quiescent Chronic Myelogenous Leukemia Stem Cells by Histone Deacetylase Inhibitors in Combination with Imatinib Mesylate

(2010) Bin Zhang et al.   CANCER CELL

Wnt/Ca2+/NFAT Signaling Maintains Survival of Ph+ Leukemia Cells upon Inhibition of Bcr-Abl

(2010) Mark A. Gregory et al.   CANCER CELL

Essential Requirement for PP2A Inhibition by the Oncogenic Receptor c-KIT Suggests PP2A Reactivation as a Strategy to Treat c-KIT+ Cancers

(2010) K. G. Roberts et al.   CANCER RESEARCH

Chronic myeloid leukemia: mechanisms of blastic transformation

(2010) Danilo Perrotti et al.   JOURNAL OF CLINICAL INVESTIGATION

Human chronic myeloid leukemia stem cells are insensitive to imatinib despite inhibition of BCR-ABL activity

(2010) Amie S. Corbin et al.   JOURNAL OF CLINICAL INVESTIGATION

Clonal chromosomal abnormalities in CD34+/CD38− hematopoietic cells from cytogenetically normal chronic myeloid leukemia patients with a complete cytogenetic response to tyrosine kinase inhibitors

(2010) T Bumm et al.   LEUKEMIA

Janus kinase 2 regulates Bcr–Abl signaling in chronic myeloid leukemia

(2010) A Samanta et al.   LEUKEMIA

AML xenograft efficiency is significantly improved in NOD/SCID-IL2RG mice constitutively expressing human SCF, GM-CSF and IL-3

(2010) M Wunderlich et al.   LEUKEMIA

Fingolimod is a potential novel therapy for multiple sclerosis

(2010) Orhan Aktas et al.   Nature Reviews Neurology

FTY720 (fingolimod) in Multiple Sclerosis: therapeutic effects in the immune and the central nervous system

(2009) Volker Brinkmann   BRITISH JOURNAL OF PHARMACOLOGY

Targeting autophagy potentiates tyrosine kinase inhibitor–induced cell death in Philadelphia chromosome–positive cells, including primary CML stem cells

(2009) Cristian Bellodi et al.   JOURNAL OF CLINICAL INVESTIGATION

Jak2 inhibition deactivates Lyn kinase through the SET–PP2A–SHP1 pathway, causing apoptosis in drug-resistant cells from chronic myelogenous leukemia patients

(2009) A K Samanta et al.   ONCOGENE

Monitoring disease response to tyrosine kinase inhibitor therapy in CML

(2009) T. P. Hughes et al.   Hematology-American Society of Hematology Education Program

Effects of Phosphorylation of Immunomodulatory Agent FTY720 (Fingolimod) on Antiproliferative Activity against Breast and Colon Cancer Cells

(2008) Yasuo Nagaoka et al.   BIOLOGICAL & PHARMACEUTICAL BULLETIN

Expansion of Bcr-Abl-Positive Leukemic Stem Cells Is Dependent on Hedgehog Pathway Activation

(2008) Christine Dierks et al.   CANCER CELL

Protein Phosphatase 2A and Rapamycin Regulate the Nuclear Localization and Activity of the Transcription Factor GLI3

(2008) S. Krauss et al.   CANCER RESEARCH

Wnt Signaling in the Niche Enforces Hematopoietic Stem Cell Quiescence and Is Necessary to Preserve Self-Renewal In Vivo

(2008) Heather E. Fleming et al.   Cell Stem Cell

β-Catenin is essential for survival of leukemic stem cells insensitive to kinase inhibition in mice with BCR-ABL-induced chronic myeloid leukemia

(2008) Y Hu et al.   LEUKEMIA

PML targeting eradicates quiescent leukaemia-initiating cells

(2008) Keisuke Ito et al.   NATURE